Singapore markets open in 1 hour 21 minutes

Kazia Therapeutics Limited (KZIA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2720-0.0105 (-3.72%)
At close: 04:00PM EDT
0.2710 -0.00 (-0.37%)
After hours: 05:31PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.2825
Open0.2990
Bid0.2710 x 100
Ask0.2788 x 100
Day's range0.2700 - 0.3100
52-week range0.1900 - 1.3900
Volume393,768
Avg. volume859,301
Market cap7.17M
Beta (5Y monthly)2.11
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

    Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the Safety Review Team (SRT) of the EVT801 Phase 1 clinical trial has concluded that the primary and secondary objectives of stage 1 of the trial have successfully been met.

  • PR Newswire

    Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

    Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that it has entered into an exclusive licensing agreement with Sovargen Co., Ltd, a biotechnology company specializing in central nervous system (CNS) diseases, to develop, manufacture and commercialise paxalisib as a potential treatment of intractable epilepsy in focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC) disease. The underlying cause of FCD T2 a

  • PR Newswire

    Kazia announces presentation of new data at AACR Annual Meeting

    Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data for both its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California, from 5-10 April 2024.